Abstract
Acquaintance is scanty on primaquine (PQ) efficacy and Plasmodium vivax recurrence in Udupi district, Karnataka, India. We assessed the efficacy of 14 days PQ regimen (0.25 mg/kg/day) to prevent P. vivax recurrence. Microscopically, aparasitemic adults (≥18 years) after acute vivax malaria on day 28 were re-enrolled into 15 months’ long follow-up study. A peripheral blood smear examination was performed with participants at every 1-2 month interval. A nested PCR test was performed to confirm the mono-infection with P. vivax. Of 114 participants, 28 (24.6%) recurred subsequently. The median (IQR) duration of the first recurrence was 3.1 (2.2-5.8) months which ranged from 1.2 to 15.1 months, including initial 28 days. Participants with history of vivax malaria had significantly higher risk of recurrence, with hazard ratio (HR) (95% CI) of 2.62 (1.24-5.54) (P = 0.012). Severity of disease (11.4%, 13/114) was not associated (P = 1.00) with recurrence. Of 28 recurrence cases, the nPCR proved that P. vivax mono-infection recurrence rate was at least 72.7% (16/22) at first recurrence. In Udupi district, PQ dose of 0.25 mg/kg/day over 14 days seems inadequate to prevent recurrence in substantial proportion of vivax malaria. Patients with a history of vivax malaria are at high risk of recurrences.
| Original language | English |
|---|---|
| Pages (from-to) | 733-742 |
| Number of pages | 10 |
| Journal | Korean Journal of Parasitology |
| Volume | 54 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - 01-12-2016 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Parasitology
- Infectious Diseases
Cite this
}
Therapeutic assessment of primaquine for radical cure of plasmodium vivax malaria at primary and tertiary care centres in Southwestern India. / Kumar, Rishikesh; Guddattu, Vasudeva; Saravu, Kavitha.
In: Korean Journal of Parasitology, Vol. 54, No. 6, 01.12.2016, p. 733-742.Research output: Contribution to journal › Article
TY - JOUR
T1 - Therapeutic assessment of primaquine for radical cure of plasmodium vivax malaria at primary and tertiary care centres in Southwestern India
AU - Kumar, Rishikesh
AU - Guddattu, Vasudeva
AU - Saravu, Kavitha
PY - 2016/12/1
Y1 - 2016/12/1
N2 - Acquaintance is scanty on primaquine (PQ) efficacy and Plasmodium vivax recurrence in Udupi district, Karnataka, India. We assessed the efficacy of 14 days PQ regimen (0.25 mg/kg/day) to prevent P. vivax recurrence. Microscopically, aparasitemic adults (≥18 years) after acute vivax malaria on day 28 were re-enrolled into 15 months’ long follow-up study. A peripheral blood smear examination was performed with participants at every 1-2 month interval. A nested PCR test was performed to confirm the mono-infection with P. vivax. Of 114 participants, 28 (24.6%) recurred subsequently. The median (IQR) duration of the first recurrence was 3.1 (2.2-5.8) months which ranged from 1.2 to 15.1 months, including initial 28 days. Participants with history of vivax malaria had significantly higher risk of recurrence, with hazard ratio (HR) (95% CI) of 2.62 (1.24-5.54) (P = 0.012). Severity of disease (11.4%, 13/114) was not associated (P = 1.00) with recurrence. Of 28 recurrence cases, the nPCR proved that P. vivax mono-infection recurrence rate was at least 72.7% (16/22) at first recurrence. In Udupi district, PQ dose of 0.25 mg/kg/day over 14 days seems inadequate to prevent recurrence in substantial proportion of vivax malaria. Patients with a history of vivax malaria are at high risk of recurrences.
AB - Acquaintance is scanty on primaquine (PQ) efficacy and Plasmodium vivax recurrence in Udupi district, Karnataka, India. We assessed the efficacy of 14 days PQ regimen (0.25 mg/kg/day) to prevent P. vivax recurrence. Microscopically, aparasitemic adults (≥18 years) after acute vivax malaria on day 28 were re-enrolled into 15 months’ long follow-up study. A peripheral blood smear examination was performed with participants at every 1-2 month interval. A nested PCR test was performed to confirm the mono-infection with P. vivax. Of 114 participants, 28 (24.6%) recurred subsequently. The median (IQR) duration of the first recurrence was 3.1 (2.2-5.8) months which ranged from 1.2 to 15.1 months, including initial 28 days. Participants with history of vivax malaria had significantly higher risk of recurrence, with hazard ratio (HR) (95% CI) of 2.62 (1.24-5.54) (P = 0.012). Severity of disease (11.4%, 13/114) was not associated (P = 1.00) with recurrence. Of 28 recurrence cases, the nPCR proved that P. vivax mono-infection recurrence rate was at least 72.7% (16/22) at first recurrence. In Udupi district, PQ dose of 0.25 mg/kg/day over 14 days seems inadequate to prevent recurrence in substantial proportion of vivax malaria. Patients with a history of vivax malaria are at high risk of recurrences.
UR - http://www.scopus.com/inward/record.url?scp=85010774013&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85010774013&partnerID=8YFLogxK
U2 - 10.3347/kjp.2016.54.6.733
DO - 10.3347/kjp.2016.54.6.733
M3 - Article
C2 - 28095658
AN - SCOPUS:85010774013
VL - 54
SP - 733
EP - 742
JO - Korean Journal of Parasitology
JF - Korean Journal of Parasitology
SN - 0023-4001
IS - 6
ER -